The C2238/αANP variant is a negative modulator of both viability and function of coronary artery smooth muscle cells

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Rubattu, Speranza ^a,b   Marchitti, Simona ^a   Bianchi, Franca ^a   Di Castro, Sara ^a   Stanzione, Rosita ^a   Cotugno, Maria ^a   Bozzao, Cristina ^b   Sciarretta, Sebastiano ^a   Volpe, Massimo ^a,b  

^a IRCCS NEUROMED   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR ALPHA; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MEMBRANE PROTEIN; MICRORNA 21; NATRIURETIC PEPTIDE TYPE C; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN PDCD4; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG; ATRIAL NATRIURETIC FACTOR; C REACTIVE PROTEIN; CREB1 PROTEIN, HUMAN; MESSENGER RNA; MICRORNA; MIRN21 MICRORNA, HUMAN; NERVE PROTEIN; NEURONAL PENTRAXIN;

APOPTOSIS; ARTICLE; CELL DAMAGE; CELL DEATH; CELL FUNCTION; CELL MIGRATION; CELL MOTILITY; CELL STIMULATION; CELL VIABILITY; CONTROLLED STUDY; CORONARY ARTERY; GENE EXPRESSION; GENE SILENCING; GENETIC VARIABILITY; HUMAN; HUMAN CELL; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE FIBER; VASOCONSTRICTION; CELL CULTURE; CELL MOTION; CELL SURVIVAL; CORONARY BLOOD VESSEL; DRUG EFFECTS; GENETIC POLYMORPHISM; GENETICS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

APOPTOSIS; ATRIAL NATRIURETIC FACTOR; BLOTTING, WESTERN; C-REACTIVE PROTEIN; CELL MOVEMENT; CELL SURVIVAL; CELLS, CULTURED; CORONARY VESSELS; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; HUMANS; MICRORNAS; MUSCLE, SMOOTH, VASCULAR; NERVE TISSUE PROTEINS; OXIDATIVE STRESS; PHOSPHORYLATION; POLYMORPHISM, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 84913598340     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0113108     Document Type: Article

References (36)

1. Rubattu S, Sciarretta S, Valenti V, Stanzione R, Volpe M (2008) Natriuretic peptides: An update on bioactivity, potential therapeutic use and implication in cardiovascular diseases. Am J Hypertens 21: 733-741.
2. Morishita R, Gibbons GH, Pratt RE, Tomita N, Kaneda Y, et al. (1994) Autocrine and paracrine effects of atrial natriuretic peptide gene transfer on vascular smooth muscle and endothelial cellular growth. J Clin Invest 94: 824- 829.
3. Kotlo KU, Hesabi B, Danziger RS (2011) Implication of microRNAs in atrial natriuretic peptide and nitric oxide signaling in vascular smooth muscle cells. Am J Physiol Cell Physiol 301: C929-C937.
4. Owens GK, Kumar MS, Wamhoff BR (2004) Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 84: 767-801.
5. Ip JH, Fuster V, Badimon I, Badimon J, Taubman MB, et al. (1990) Syndromes of accelerated atherosclerosis: role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 15: 1667-1687.
6. Wang X-P, Zhang W, Liu X-Q, Wang W-K, Yan F, et al. (2014) Arginase I enhances atherosclerotic plaque stabilization by inhibiting inflammation and promoting smooth muscle cell proliferation. Eur Heart J 35: 911-919.
7. Gruchala M, Ciecwierz D, Wasag B, Targonski R, Dubaniewicz W, et al. (2003) Association of the ScaI atrial natriuretic peptide gene polymorphism with nonfatal myocardial infarction and extent of coronary artery disease. Am Heart J 145: 125-131.
8. Rubattu S, Stanzione R, Di Angelantonio E, Zanda B, Evangelista A, et al. (2004) Atrial natriuretic peptide gene polymorphisms and risk of ischemic stroke in humans. Stroke 35: 814-818.
9. Barbato E, Bartunek J, Mangiacapra F, Sciarretta S, Stanzione R, et al. (2012) Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease. J Am Coll Cardiol 59: 1763-1770.
10. Cannone V, Huntley BK, Olson TM, Heublein DM, Scott CG, et al. (2013) Atrial natriuretic peptide gene variant rs5065 and risk for cardiovascular disease in the general community: A 9-year follow-up study. Hypertension 62: 860-865.
11. Ziaee S, Kalayinia S, Boroumand MA, Pourgholi L, Cheraghi S, et al. (2014) Association between the atrial natriuretic peptide rs5065 gene polymorphism and the presence and severity of coronary artery disease in an Iranian population. Coron Artery Dis 25: 242-246.
12. Rubattu S, De Giusti M, Farcomeni A, Abbolito S, Comito F, et al. (2014) T2238C ANP gene variant and risk of recurrent acute coronary syndromes in an Italian cohort of ischemic heart disease patients. J Cardiovasc Medic in press.
13. Sciarretta S, Marchitti S, Bianchi F, Moyes A, Barbato E, et al. (2013) The C2238 atrial natriuretic peptide molecular variant is associated with endothelial damage and dysfunction through natriuretic peptide receptor C signaling. Circ Res 112: 1355-1364.
14. Lin X, Hanze J, Heese F, Sodmann R, Lang RE (1995) Gene expression of natriuretic peptide receptors in myocardial cells. Circ Res 77: 750-758.
15. Weber W, Fischli W, Hochuli E, Kupfer E, Weibel EK. (1991) Anantin-a peptide antagonist of the atrial natriuretic factor (ANF). I. Producing organism, fermentation, isolation and biological activity. J Antibiot 44: 164-171.
16. Scarpino S, Marchitti S, Stanzione R, Evangelista A, Di Castro S, et al. (2009) ROS-mediated differential effects of the human atrial natriuretic peptide T2238C genetic variant on endothelial cells invitro. J Hypertens 27: 1804-1813.
17. Ji R, Cheng Y, Yue J, Yang J, Liu X, et al. (2007) MicroRNA expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neointima formation. Circ Res 100: 1579-1588.
18. Quintavalle C, Garofalo M, Croce CM, Condorelli G (2011) ApoptomiRs in vascular cells: their role in physiological and pathological angiogenesis. Vascul Pharmacol 55: 87-91.
19. Song JT, Hu B, Yan Qu H, Bi CI, Huang XZ, et al. (2012) Mechanical stretch modulates MicroRNA 21 expression, participating in proliferation and apoptosis in cultured human aortic smooth muscle cells. Plos One 7: e47657.
20. Hiroshi I, Pratt RE, Dzau VJ (1990) Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest 86: 1690-1697.
21. Volpe M, Rubattu S, Burnett J Jr (2014). Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur. Heart J 35: 419-425.
22. Villar IC, Panayiotou CM, Sheraz A, Madhani M, Scotland RS, et al. (2007) Definitive role for natriuretic peptide receptor-C in mediating the vasorelaxant activity of C-type natriuretic peptide and endothelium-derived hyperpolarising factor. Cardiovasc Res 74: 515-525.
23. Cheng Y, Zhang C (2010) MicroRNA-21 in cardiovascular disease. J Cardiovasc Trans Res 3: 251-255.
24. Roy S, Khanna S, Hussain SR, Biswas S, Azad A, et al. (2009) MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatide and tensin homologue. Cardiovasc Res 82: 21-29.
25. Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM, et al. (2004) The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol 37: 449-471.
26. Bellis A, Castaldo D, Trimarco V, Monti MG, Chivasso P, et al. (2009) Crosstalk between PKA and Akt protects endothelial cells from apoptosis in the late ischemic preconditioning. Arterioscler Thromb Vasc Biol 29: 1207-1212.
27. Lovren F, Pan Y, Shukla PC, Quan A, Teoh H, et al. (2009). Visfatin activates eNOS via Akt and MAP kinases and improves endothelial cell function and angiogenesis in vitro and in vivo: translational implications for atherosclerosis. Am J Physiol Endocrinol Metab 296: E1440-E1449.
28. Lu Y, Zhang Y, Shan H, Pan Z, Li X, et al. (2009) MicroRNA-1 downregulation by propanolol in a rat model of myocardial infarction: A new mechanism for ischaemic cardioprotection. Cardiovasc Res 84: 434-441.
29. Shu M, Zhou Y, Zhu W, Zhang H, Wu S, et al. (2012) MicroRNA 335 is required for differentiation of malignant glioma cells induced by activation of cAMP/Protein Kinase A pathway. Mol Pharmacol 81: 292-298.
30. Keller DM, Clark EA, Goodman RH (2012) Regulation of microRNA-375 by cAMP in pancreatic b-cells. Mol Endocrinol 26: 989-999.
31. Ridley AJ, Schwartz MA, Burridge K, Firtel RA, Ginsberg MH, et al. (2003) Cell migration: integrating signals from front to back. Science 302: 1704-1709.
32. Schwartz SM, Campbell GR, Campbell JH (1986) Replication of smooth muscle cells in vascular disease. Circ Res 58: 427-444.
33. Zhou Y, Yan H, Guo M, Zhu J, Xiao Q, et al. (2013) Reactive oxygen species in vascular formation and development. Oxid Med Cell Longev 2013: 374963.
34. Zimmerman MC, Takapoo M, Jagadeesha DK, Stanic B, Banfi B, et al. (2011) Activation of NADPH oxidase 1 increases intracellular calcium and migration of smooth muscle cells. Hypertension 58: 446-453.
35. Kang H, Davis-Dusenbery BN, Nguyen PH, Lal A, Lieberman J, et al. (2012) Bone morphogenetic protein 4 promotes vascular smooth muscle contractility by activating microRNA-21 (miR-21), which down-regulates expression of family of dedicator of cytokinesis (DOCK) proteins. J Biol Chem 287: 3976-3986.
36. Martinez-Hervas S, Vinue A, Nunez L, Andres-Blasco I, Piqueras L, et al. (2014) Insulin resistance aggravates atherosclerosis by reducing vascular smooth muscle cell survival and increasing CX3CL1/CX3CR1 axis. Cardiovasc Res 103: 324- 336.